Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 135

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 135
---
 • |     | shares of our common stock issuable upon the exercise of common stock warrants                                                                                     
 outstanding as of     , with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Series B-1 
 Warrants;”                                                                                                                                                         |

| • |     | shares of our common stock issuable upon the exercise of common stock warrants                                                                                                  
 outstanding as of     , with an exercise price of $1.50 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—New Series B Warrants;” |

| • |     | shares of common stock reserved for future issuance under our 2025 Plan, which became                                                                                                                                                                     
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully described in 
 the section titled “Executive Compensation—Equity Benefit Plans;” and                                                                                                                                                                                     |

| • |     | shares of common stock reserved for future issuance under our ESPP, which became                                                                                                                                                                         
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more fully described 
 in the section titled “Executive Compensation—Equity Benefit Plans.”                                                                                                                                                                                     |

90

DILUTION If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. Our historical net tangible book value as of was $ million, or $ per share of common stock. Our historical net tangible book value (deficit) per share represents the amount of our total tangible assets less our total liabilities and redeemable convertible preferred stock, divided by the total number of shares of common stock outstanding as of . Our pro forma net tangible book value as of was $ million, or $ per share of our common stock. Pro forma net tangible book value per share represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock and the related reclassification of the carrying